Please login to the form below

azacitidine

This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit

Latest news

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020. Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory ... The formulation – known as CC-486 – is an
Tecentriq’s triple negative breast cancer use among key CHMP nods

The drug gained FDA approval in December 2017. Celgene also received a positive opinion for azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloidleukaemia.
Dutch biotech Argenx claims $1.8bn licensing deal with J&J

It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.
Pfizer gets first FDA nod for hedgehog inhibitor in AML

And in a bumper day for the therapeutic category, the FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethyelating agent (azacitidine or decitabine) for the exact
Celgene, Agios get FDA OK for leukaemia drug Idhifa

At Celgene, enasidenib will slot into its blood cancer therapy portfolio alongside Vidaza (azacitidine), a drug used first-line to treat AML patients who cannot receive a stem cell transplant, which

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Consultant: competitive salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Manager– Medical Communications: (Negotiable - depending on experience)

Senior Medical Writer, MedComms Agency: Salary TBC

Vice President: Competitive Salary Offered

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

White Paper for download - Explaining the price of your product: In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team: Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
The changing nature of approvals – what does the future hold?: The 2019 CMR International Pharmaceutical R&D Factbook...